미국 · 보도자료 · PLSE · 2026-10-07 11:00
심방세동 치료 카테터 nPulse 임상 환자 모집 목표 달성
HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nano-PFA or nsPFA™) technology, today announced that its NANOPULSE-AF Study has reached its enrollment target of 164 evaluable patients across 15 clinical sites. "The compelling first-in-human dataset from the nPulse Cardiac Catheter System cre
